Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Boston. Schedule A details four specific debt issuances with trade dates in July 2026, ranging from $10 million to $50 million in principal amount, with maturity dates between 2027 and 2031. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations created by the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a par value of $15,000,000, a 5-year maturity (7/14/2026 to 7/14/2031), and a 4.875% fixed coupon. This is a direct creation of a new financial obligation under Item 2.03, meeting the definition of debt issuance. The settlement date of 7/14/2026 confirms the obligation has been incurred.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details three bond issuances with trade dates of 7/8/2026 and 7/9/2026, totaling $50 million in par amount, with maturities ranging from 2028 to 2051. This is a classic debt_issuance event under Item 2.03, representing new direct financial obligations of the registrant.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (>US$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M&A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-14
Item 5.02
The filing discloses the appointment of Michael Jennings and Zamir Rauf to the Board of Directors of the General Partner, effective July 14, 2026, with detailed descriptions of their qualifications and committee assignments. While the disclosure also includes compensatory arrangements (phantom units and cash fees) and the resignations of two directors, the principal action is the appointment of two new independent directors with substantial energy-sector experience. This is material to investors as board composition affects governance and oversight.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 8.01
Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-14
Item 5.03
Genprex stockholders approved a 1-for-22 reverse stock split on June 18, 2026, which was effectuated via Certificate of Amendment filed July 13, 2026. The reverse split materially affects shareholder rights and capital structure by consolidating shares and altering per-share metrics.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic analyses, and Phase 2 study findings for an 80 mg BID dose. These data support the company's planned Phase 3 trial design and dose selection, representing a material clinical development milestone for the company's lead drug candidate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-14
Item 2.02
Loop Industries issued a press release on July 14, 2026 announcing its consolidated financial results for the first quarter of fiscal year 2027, including revenues of $179 thousand, net loss of $3,385 thousand, and cash position of $1,063 thousand. The filing explicitly states "Loop Industries, Inc. (the 'Company') issued a press release announcing its financial results for the first quarter of fiscal year ending February 28, 2027" with the press release attached as Exhibit 99.1, which is the standard format for an earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from a Special Meeting held on July 13, 2026. The filing reports final voting tallies for two proposals: (1) approval of a reverse stock split at a ratio to be determined by the Board (9,131,707 for, 115,909 against), and (2) approval of an amendment to increase authorized capital stock from 46 million to 1.001 billion shares (6,700,459 for, 89,041 against). Both proposals passed with overwhelming majorities and are material to investors as they affect share structure and capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-14
Item 1.01
Bridgeline Digital entered into an at-the-market (ATM) offering agreement with WestPark Capital to sell shares of common stock on a registered basis under Form S-3. While technically registered (not unregistered), ATM offerings are economically equivalent to dilutive equity issuances and represent a material capital-raising mechanism that creates ongoing dilution risk to existing shareholders. The agreement grants the company discretion to sell shares at market prices, making this a material financing event typical of small-cap issuers raising capital.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-07-14
Item 7.01
The filing discloses unaudited condensed consolidated interim financial statements and MD&A for the three and six months ended May 31, 2026, filed via Form 6-K by the parent company GoldMining Inc. on July 14, 2026. Although furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the core disclosure is interim financial results—a periodic earnings release. The statements show a net loss of $16.5 million for the six-month period and include comprehensive income data, cash flows, and balance sheet information typical of an interim earnings disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
QumulusAI issued fiscal year 2026 guidance disclosing forward ARR of $300 million (~30x growth) and 18 MW of capacity with line of sight to 2.5 GW by 2027. While this resembles an earnings release or forward guidance, it is disclosed under Item 7.01 (Regulation FD Disclosure) as an "investor outlook update" rather than as a formal earnings release tied to quarterly/annual results. The disclosure centers on operational metrics (ARR and capacity expansion) and strategic business outlook rather than historical financial results, making it an operational/strategic disclosure material to investors assessing the company's growth trajectory and infrastructure deployment plans.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-14
Item 5.02
Ms. Anya Hamill, the Chief Financial Officer, notified the Company on July 9, 2026 of her resignation effective August 31, 2026. The disclosure centers on the departure of a named executive officer from a material position. The filing explicitly states there are no disagreements or issues regarding financial statements or internal controls, indicating a routine departure rather than a governance crisis, but CFO departures are material events that affect investor assessment of the registrant's financial leadership and continuity.
View raw filing on EDGAR →
6-K
Governance Other
confidence 92%
filed 2026-07-14
EX-99.1
This is a proxy statement and notice of shareholder meetings (Class B Meeting and Extraordinary General Meeting) scheduled for July 22, 2026. The document discloses multiple governance proposals including: (1) variation of Class B Ordinary Share voting rights from 20 to 100 votes per share; (2) increase of authorized shares from 600 million to 5 billion; (3) adoption of amended memorandum and articles of association; (4) share consolidation authorization up to 2,000-for-1 ratio. These are material governance and capital structure changes requiring shareholder approval, making this a governance event that does not fit a specific named category (not a vote result, but the notice/proxy for upcoming votes).
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-07-14
EX-99.1
Youxin Technology announced a non-binding term sheet to make a strategic investment of US$20 million in RiverBit Holding Limited to acquire a 10% equity interest upon achievement of operating milestones (2,000 daily users and US$100 million daily trading volume within three months of launch). Although non-binding and contingent on due diligence and definitive agreements, this represents a material acquisition of a minority equity interest in a third party, which falls within the scope of M&A activity disclosures. The investment amount and strategic nature would affect a reasonable investor's assessment of the company's capital allocation and business strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-07-14
The filing's primary disclosure is Item 5.07, which reports the results of the July 9, 2026 Annual Meeting of Stockholders, including voting outcomes on four proposals: director election (Jeff Hargroves), auditor ratification (KPMG LLP), equity plan amendment (625,000 additional shares), and meeting adjournment. While the filing also contains Item 5.02 disclosures regarding board structure changes and equity plan amendments, the central event is the shareholder vote results with specific vote tallies for each proposal, making shareholder_vote_results the most salient classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
Almonty announced an amendment to its long-term offtake agreement with Global Tungsten & Powders that extends the contract term from 15 to 21 years, increases contracted volumes by 40% to 4.41 million MTU, and improves pricing by 6.3%, resulting in US$490 million in total contracted annual revenue at current pricing. This is a material operational and commercial event—a significant expansion of a key supply contract covering approximately 90% of Phase I production from the Sangdong Mine—that would affect a reasonable investor's assessment of the company's revenue visibility and strategic positioning in the tungsten market.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-14
CL Workshop Group Limited entered into a securities purchase agreement on July 14, 2026, for a private placement of 12,300,000 units at US$0.20 per unit, generating approximately US$2.46 million in gross proceeds plus potential additional proceeds of US$9.225 million upon warrant exercise. This is a classic dilutive issuance of unregistered equity securities (ADSs and warrants) sold in reliance on Section 4(a)(2) and Regulation S exemptions, materially affecting shareholder ownership and the capital structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-14
EX-99.1
The exhibit is a press release announcing the appointment of Gadi Levin as Chief Financial Officer of A2Z Cust2Mate Solutions Corp. effective immediately. The disclosure explicitly states "Gadi Levin has been appointed Chief Financial Officer" and includes quotes from the Executive Chair endorsing his qualifications and experience. This is a clear executive appointment of a named executive officer to a material position.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-14
Item 5.02
The filing discloses board approval on July 10, 2026 of restricted stock unit (RSU) awards to directors and officers, including CEO Vuong Trieu (2,000 RSUs), Chief Medical Officer Anthony Maida (1,500 RSUs), and other named executives. The RSUs are contingent equity compensation subject to performance and time-based vesting tied to uplisting onto a national stock exchange by June 30, 2027. This is a compensatory arrangement for named executives and directors, squarely within Item 5.02(e) disclosure requirements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-14
Item 5.02
The filing discloses both a director departure (Annie Van Broekhoven's retirement and resignation from the Board effective July 8, 2026) and a director appointment (Carlo Campiciano appointed to the Board the same day). While both events occurred, the principal disclosed action centers on the appointment of Campiciano, with detailed biographical information provided about his qualifications, experience as CFO and Company Secretary of MedAdvisor Limited, and expertise in finance, taxation, and corporate governance. The appointment is the forward-looking action that fills the vacancy and is material to investors assessing board composition.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-07-14
The 6-K discloses a court order by the Court of Milan (July 9, 2026) revoking a preliminary suspension order and restoring the effectiveness of a corporate purpose amendment to the Company's bylaws. This is a material legal/regulatory event affecting the Company's strategic initiatives and governance. The underlying civil action challenging the validity of shareholder resolutions remains pending, but the immediate disclosure concerns the successful outcome of the precautionary appeal, which the Court determined favored the Company's interest in maintaining the amendment's effectiveness given significant investments already made.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-07-14
The 6-K discloses two material executive changes effective July 1, 2026: Mr. Hiroshi Furukawa's promotion from CEO to Chairman and CTO, and Mr. Hideaki Horikiri's promotion from CFO to President and COO. While the filing also mentions Mr. Toshihito Kanai's resignation as CTO and Director, the principal disclosed actions are the appointments/promotions of Furukawa and Horikiri to new executive roles. Both remain principal executive and financial officers respectively under SOX, making these material governance events affecting leadership structure.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-07-14
EX-99.1
This is a convocation notice for an Extraordinary General Meeting of Shareholders that includes three substantive governance proposals: (1) amendments to the Articles of Incorporation affecting authorized share structure and officer roles; (2) preferential issuance of up to 20 million Class A Preferred Shares to a special subscriber (About Investment Pte. Ltd.) at $0.25/share to address "unfavorable financial position" and going-concern needs; and (3) election of two independent directors. While Proposal 2 involves a dilutive equity issuance and implicit going-concern language, the exhibit is fundamentally a shareholder meeting notice and governance document rather than a discrete event announcement. The material substance—capital raise, going-concern pressure, and control dilution—is embedded in the meeting agenda rather than disclosed as a standalone event, making this a governance-domain disclosure that does not fit the specific event types (dilutive_issuance or going_concern would apply to the underlying transaction, but this is the notice convening the vote).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-14
Item 2.03
Item 2.03 discloses creation of a direct financial obligation, with a Promissory Note dated July 8, 2026 attached as Exhibit 10.1. This is a classic debt issuance event. The filing references incorporation of Item 1.01 details (not shown here), which likely contains the material terms. For a biotech company like Evofem, debt issuance is material to investor assessment of capital structure and financial position.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-14
The filing discloses multiple governance events on July 14, 2026: the voluntary resignations of two board members (David Johnson and Nino Pionati), the appointment of two new directors (Zvi Joseph and Lior Buchman) to fill those vacancies, and the appointment of Zeev Rotstein, M.D. as the new Board Chairman. While both departures and appointments occur, the filing treats them as a coordinated board transition rather than emphasizing either departure or appointment alone. The changes affect board composition and committee assignments, making this a material governance restructuring that would affect investor assessment of the company's leadership.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01 discloses that on July 8, 2026, SBC Medical Group notified Nasdaq that it would cease compliance with Nasdaq independence rules for board and audit committee membership due to Mike Sayama's departure. On July 10, 2026, Nasdaq formally notified the Company of non-compliance with Listing Rule 5605 and granted a cure period until the earlier of the next annual shareholders' meeting or July 9, 2027. This is a material delisting risk event requiring immediate remediation through appointment of independent directors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
The filing discloses results of a Special Meeting of Stockholders held on July 9, 2026, with voting outcomes on three proposals: approval of an Additional Investment Right, approval of a Share Issuance, and approval of an Increase in Authorized Shares. All three proposals were approved by requisite vote. This is a classic Item 5.07 shareholder vote results disclosure, and the share issuance and authorized share increase proposals are material to investors as they affect capital structure and dilution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
The filing discloses FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- breast cancer and the company's anticipated commercial launch in late Q3 2026, along with plans to submit a supplemental NDA for PIK3CA-mutated patients. This is a material regulatory milestone and product approval event that does not fit neatly into the standard financial, governance, or legal categories—it is primarily an operational/strategic business milestone involving regulatory approval and commercialization of the company's lead product candidate.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 75%
filed 2026-07-14
The filing discloses a trading halt by NYSE Regulation due to "abnormally low trading price" and explicitly states "the risk that NYSE American may delist our Common Stock" and "the risk that NYSE American may not timely remove any trading halt." While the reverse stock split is the primary action disclosed, the material event driving the filing is the delisting risk and trading halt, which are the triggering circumstances necessitating the reverse split to restore compliance with NYSE American listing standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-07-14
EX-99.1
The announcement discloses a 12-for-1 share consolidation effected on July 14, 2026, explicitly stated as undertaken "to ensure the Company's ongoing compliance with Nasdaq Marketplace Rule 5550(a)(2) in order to maintain its listing on Nasdaq." This is a direct response to a delisting risk — the company's share price had fallen below the minimum bid price threshold required by Nasdaq's continued listing standards. The consolidation is a remedial action to avoid delisting, making this a material disclosure of delisting risk and the company's response to it.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This announcement discloses completion of a technical field scouting program and planned geophysical survey on the M47 exploration licence in Türkiye. The disclosure describes operational exploration activities—geological validation, gravity studies, and planned seismic acquisition—that advance the company's development of a material asset (a 29% working interest with US$15 million funding commitment). While the event is clearly operational and strategic in nature, it does not fit the specific named categories (no M&A, no workforce reduction, no material contract announcement per se). The materiality derives from the company's focus on this block and the resource potential previously disclosed (27.6 MMbbl contingent resource with US$733.5M NPV-10), making exploration progress on this asset material to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
This press release announces an amendment to the M47 Farm-In Agreement that restructures and extends payment obligations under Trillion's earn-in commitment for a 29% participating interest in an onshore oil exploration block in Türkiye. The amendment extends the next tranche payment deadline to September 15, 2026 (approximately USD$4.35 million) and postpones further payments until September 2027, providing material financial flexibility. While the core transaction (the farm-in agreement itself) was previously disclosed in January 2026, this amendment materially alters the payment schedule and timing of the Company's financial commitments, which is operationally and strategically significant for an exploration company managing cash flow and development timelines.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-07-14
Item 1.01
Two Hands Corp sold a $132,000 convertible promissory note (net funding $125,000) to Vanquish Funding Group, convertible into common stock at 75% of the lowest closing bid price during the 10 trading days prior to conversion. The unregistered sale was made under Section 4(a)(2) exemption to an accredited investor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-14
Item 3.02
The filing discloses unregistered sales of equity securities under Item 3.02, involving the issuance of approximately 1.26 million shares of common stock (77,360 + 1,018,585 + 167,400) to existing preferred stockholders in exchange for preferred shares. The transactions rely on Section 3(a)(9) exemption and result in significant dilution to common shareholders. While structured as preferred-for-common exchanges rather than cash-raising private placements, the net effect is a material dilutive issuance of unregistered common equity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-14
Item 8.01
Morgan Stanley Capital I Inc. issued BANK5 2026-5YR23 Commercial Mortgage Pass-Through Certificates on July 14, 2026, creating a new direct financial obligation backed by a pool of 33 commercial and multifamily mortgage loans. The Publicly Offered Certificates had an aggregate certificate balance of $991.5 million with net proceeds of approximately $1.048 billion, representing a material debt issuance. This is a securitization transaction creating new debt instruments, distinct from a typical corporate bond but functionally equivalent as a creation of direct financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-14
Item 7.01
The filing announces Liberty Media's second quarter 2026 earnings release and conference call scheduled for August 6, 2026. The press release (Exhibit 99.1) explicitly states "Liberty Media Corporation Announces Second Quarter Earnings Release and Conference Call" and confirms that "Before the open of market trading that day, Liberty Media will issue a press release reporting such results." This is a material disclosure of quarterly financial results, even though the actual results are not yet included in this announcement—the announcement itself is the earnings release notification.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-14
Item 8.01
News Corporation disclosed daily buy-back notifications under its $1 billion repurchase program authorized as of July 15, 2025. The Item 8.01 disclosure reports that on July 14, 2026, the Company purchased 9,312,074 Class A shares and 66,163 Class B shares for approximately $236.6 million combined, with approximately $364.3 million spent to date under the program. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return-of-capital mechanism, distinct from operational or financial events.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-14
Item 5.02
Alex Shootman was appointed to PagerDuty's Board of Directors effective July 14, 2026, and simultaneously appointed to the Audit Committee and Compensation Committee. Shootman brings 25+ years of operating experience and prior CEO roles at Workfront and Eloqua, representing a material change to the company's board composition and governance oversight.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-14
Item 2.02
Virtu Financial issued a press release on July 14, 2026, disclosing preliminary estimated results of operations for the quarter ended June 30, 2026, including net income of $285 million, EPS of $1.63, trading income of $857 million, and Adjusted EBITDA of $437 million. The preliminary estimates were disclosed in connection with marketing incremental term loans, with final results to be reported on July 30, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-14
Item 8.01
This Item 8.01 discloses a supplement to the definitive proxy statement for a merger transaction. The core event is the pending merger between Avanos and A-AV Holdco I, Inc., with stockholder approval scheduled for July 22, 2026. Although the filing addresses litigation and supplemental disclosures, the material event is the merger activity itself—a change of control transaction that was previously disclosed on April 13, 2026, and is now being supplemented in response to stockholder litigation and demand letters. The supplement updates key merger-related disclosures including financial forecasts, valuation analyses, and conflict-of-interest information, all central to the merger transaction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-07-14
Item 2.02
This Item 2.02 disclosure presents preliminary summary financial information for Q2 2026, including realized commodity prices (oil, NGLs, gas) and a material $190 million loss from commodity derivative settlements. Although explicitly labeled as preliminary and unaudited, the disclosure of quarterly operational results and derivative losses is characteristic of an earnings-related disclosure under Item 2.02, which would materially affect investor assessment of the company's financial performance and hedging outcomes.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
Talen Energy announced results from the PJM Base Residual Auction for 2028/2029, clearing 10,180 megawatts at $325/MW-day, equating to approximately $1.208 billion in capacity revenues. This is a material operational and commercial milestone for an independent power producer, reflecting successful capacity procurement in a key wholesale market, but does not fit the specific categories of earnings release, debt issuance, M&A, or other named event types. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02 (Results of Operations), and represents a significant commercial achievement rather than periodic financial results.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-14
The 6-K discloses KT Corporation's decision to pay a quarterly cash dividend of 600 KRW per common share, with a total dividend payment of 142,578,831,000 KRW and a record date of July 29, 2026. This is a routine but material capital distribution to shareholders, approved by the Board of Directors on July 14, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-14
Item 2.02
JPMorgan Chase disclosed its second quarter 2026 financial results on July 14, 2026, reporting net income of $21.2 billion ($7.70 per share), up 41% from the prior-year quarter. The filing includes a complete earnings release with detailed segment results, capital metrics, and forward-looking commentary from CEO Jamie Dimon. This is a standard quarterly earnings disclosure material to investors assessing the firm's financial performance and capital position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-14
Item 7.01
JPMorgan Chase held an investor presentation on July 14, 2026 to review 2Q26 earnings and furnished presentation slides (Exhibit 99) disclosing comprehensive financial results including net income of $21.2B, EPS of $7.70, revenue of $58.0B, and detailed performance metrics by business segment. This is a classic earnings release disclosure under Item 7.01 (Regulation FD Disclosure), with the earnings presentation slides attached as an exhibit.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-14
Item 7.01
Lucid Group issued a public denial of rumors regarding bankruptcy exploration, special board committees, and liquidity concerns, while confirming engagement with AlixPartners for operational improvement. The disclosure addresses material investor concerns about the company's financial viability and governance, but does not fit neatly into standard 8-K categories—it is neither a going-concern statement (which would affirmatively disclose substantial doubt), nor a restatement, covenant breach, or other defined event. The materiality lies in the company's need to publicly refute market rumors affecting investor confidence, making this a material event that does not fit a specific taxonomy category.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-14
Item 2.03
Davey Tree entered into a Fifteenth Amendment to its Receivables Financing Agreement with PNC Bank on July 10, 2026, extending the facility's termination date by two years to July 10, 2028, and modifying key terms including removal of a SOFR adjustment and addition of a maximum Leverage Ratio covenant of 3.75:1.00. This material modification extends the company's borrowing capacity and imposes new financial covenants.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-14
Item 5.02
Robert A. Parks' resignation as Chief Accounting Officer effective August 7, 2026, is the primary disclosed action in the first section. While the filing also covers Carrie Russell's appointment as interim CAO and Jill McConnell's previously announced CFO departure with severance arrangements, the central focus of the Item 5.02 disclosure is Parks' departure from a principal accounting officer role. The appointment of Russell as interim successor and the compensation arrangements are secondary to the departure event itself.
View raw filing on EDGAR →